Tetra Bio-Pharma Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TBPMF research report →
Companywww.tetrabiopharma.com
Tetra Bio-Pharma Inc. , a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; REBORN for the treatment of breakthrough cancer pain; Reduvo for chemotherapy-induced nausea and vomiting; ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; and SERENITY to treat cancer cachexia.
- CEO
- Guy Chamberland Master Herbal
- IPO
- 2012
- Employees
- 33
- HQ
- Orléans, ON, CA
Price Chart
Valuation
- Market Cap
- $7.87M
- P/E
- -0.21
- P/S
- 0.00
- P/B
- 44.69
- EV/EBITDA
- -0.18
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -467.81%
- ROIC
- -739.13%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-52,175,046 · -97.06%
- EPS
- $-0.12 · -20.00%
- Op Income
- $-24,841,290
- FCF YoY
- -21.29%
Performance & Tape
- 52W High
- $0.10
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.01
- Beta
- 1.98
- Avg Volume
- 365.00K
Get TickerSpark's AI analysis on TBPMF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our TBPMF Coverage
We haven't published any research on TBPMF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TBPMF Report →